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Abstract
Human mitochondrial complex II is an intriguing enzyme, which has been the focus of 
medical research during the past few decades since it contributes to pathogenesis of mito-
chondrial diseases as well as a target for chemotherapy. Reactive oxygen species (ROS) pro-
duced by this enzyme has been implicated in both these conditions. While ROS produced 
from mutated mitochondrial complex II has been implicated in pathogenesis of mitochon-
drial diseases, ROS produced from pharmacologically inhibited mitochondrial complex II 
has been implicated in cancer cell death. In this chapter, we show that inhibition of mito-
chondrial complex II in human cancer cells with atpenin A5 produces detectable levels of 
ROS while normal cells do not. Thus, this enzyme may be used as a potential target for 
developing new anticancer drugs to trigger ROS-mediated selective death of cancer cells.
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1. Introduction
Human mitochondrial complex II (succinate:ubiquinone oxidoreductase; succinate dehydro-
genase (SDH)) is an intriguing enzyme, which has been the focus of medical research during 
the past few decades since it contributes to pathogenesis of mitochondrial diseases (for recent 
reviews, see [1, 2]) and also a target for chemotherapy [3–5].
1.1. Structure of mitochondrial complex II
Mitochondrial complex II is a heterotetrameric protein embedded in the inner mitochondrial 
membrane. Its four subunits are referred as flavoprotein subunit (Fp), iron-sulfur subunit 
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(Ip), cytochrome b large subunit (CybL), and cytochrome b small subunit (CybS). The Fp and 
Ip subunits comprise the catalytic domain of the enzyme. The Fp subunit has a flavin adenine 
dinucleotide (FAD) as a prosthetic group and contains the dicarboxylate-binding site, which 
serves as the binding site for succinate and fumarate. The Ip subunit generally contains three 
iron-sulfur clusters [2Fe-2S]2+,1+, [4Fe-4S]2+,1+, and [3Fe-4S]1+,0 as prosthetic groups. Subunits 
CybL and CybS, with heme b as the prosthetic group, form the anchor domain of the enzyme. 
This anchors the catalytic domain to the inner mitochondrial membrane and also forms the 
quinone (Q)-binding site, together with the Ip subunit [6, 7] (Figure 1).
In 2003, our laboratory revealed that human mitochondrial complex II exists in two isoforms, 
which differ in the Fp subunit. These two human Fp subunits, which are referred as Fp I and 
Fp II, differ only in two amino acids in the C-terminal of the protein-Tyr629Phe and Val657Ile 
[8, 9]. The majority of human tissues have shown expression of both isoforms of complex II 
with predominant expression of type I Fp. However, some cancer cell lines and fetal tissues 
have shown predominant expression of type II Fp also [4]. Furthermore, type II Fp expres-
sion has been found to increase in cultured cells under ischemic conditions [10]. Moreover, 
our laboratory has revealed that Fp subunit of human complex II undergoes posttranslational 
modifications by phosphorylation of its tyrosine, threonine, and serine residues under tumor 
mimicking microenvironments (hypoxic and hypoglycemic conditions), which affects its 
enzymatic activity [11].
Figure 1. Schematic representation of the mitochondrial complex II. The four subunits of the complex II, namely the 
flavoprotein subunit, iron sulfur subunit, cytochrome b large subunit, and cytochrome b small subunit are labeled as Fp, 
Ip, CybL, and CybS, respectively. The prosthetic groups that participate in the electron transfer are the flavin adenine 
dinucleotide (FAD), three iron sulfur clusters 2Fe-2S, 3Fe-4S, 4Fe-4S, and heme b. Dicarboxylate-binding site in the Fp 
subunit serves as the catalytic site for succinate oxidation/fumarate reduction. Quinone-binding site comprised of Ip, 
CybL, and CybS subunits serves as the catalytic site for quinone reduction/quinol oxidation.
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1.2. Function of mitochondrial complex II
In human cells, this enzyme plays dual roles as an indispensable enzyme in the TCA cycle 
as well as in the aerobic respiratory chain (Figure 2). It oxidizes succinate to fumarate in the 
TCA cycle and reduces quinone to quinol in the aerobic respiratory chain [6, 12]. This is in 
contrast to the function of the mitochondrial complex II of the anaerobic organisms such as 
Ascaris suum, which oxidizes quinol into quinone that is coupled with reduction of fumarate 
to succinate (Figure 3) [13]. However, our laboratory has revealed distinct fumarate reductase 
(FRD) activity in the human cancer cells, which have significantly increased upon exposure 
to hypoxia and hypoglycemia. In these cells, mitochondrial complex II is reported to acquire 
FRD activity through phosphorylation of its Fp subunit [11]. This finding is further supported 
Figure 2. Schematic representation of the function of the mitochondrial complex II in the aerobic respiratory chain 
and the TCA cycle. Functioning as a component of the TCA cycle, mitochondrial complex II catalyzes the oxidation of 
succinate to fumarate with transfer of electrons to FAD. Functioning as a component of the aerobic respiratory chain, 
the electrons on FAD are transferred through Fe-S clusters and heme b to reduce the ubiquinone. For simplicity of the 
representation, the subunit composition of the respiratory chain complexes I, III, IV, and V is not shown.
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by recent metabolic profiling studies also on gastric and colon carcinomas [14]. In addition to 
its role in energy metabolism, mitochondrial complex II has been identified to have a novel 
function as a tumor suppressor in certain tissues. Mutations in its subunits are reported to 
cause cancers such as pheochromocytoma (tumors of the chromaffin cells in the adrenal 
medulla) and paraganglioma (extra adrenal tumors of sympathetic or parasympathetic ori-
gin). Moreover, breast, thyroid, and renal carcinomas are also known to be associated with 
complex II mutations. More recently, mutations in the complex II assembly factors, succinate 
dehydrogenase assembly factor 1 (SDHAF1) and succinate dehydrogenase assembly factor 2 
(SDHAF2), are also reported to be linked with infantile leukoencephalopathy and paragan-
glioma (for a recent review, see [2]).
Figure 3. A schematic representation of the function of the mitochondrial complex II in the anaerobic respiratory chain. 
Electrons originating from NADH oxidation in complex I reduce the rhodoquinone (RQ) to rhodoquinol (RQH2) at its Q 
site. Rhodoquinol is subsequently oxidized to rhodoquinone at the Q site of the complex II. The resulting electrons are 
transferred via the Fe-S clusters and FAD to reduce fumarate to succinate. Fumarate is the terminal electron acceptor of 
the anaerobic respiratory chain.
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1.3. ROS production from mitochondrial complex II
Reactive oxygen species (ROS) are inevitable byproducts of the aerobic respiratory chain. 
Major ROS produced by the respiratory chain is superoxide (O
2
−). It is subsequently dis-
mutated into hydrogen peroxide (H
2
O
2
) by superoxide dismutase (Figure 4). Both O
2
− and 
H
2
O
2
 are known to contribute to physiological and pathological redox signaling [15, 16].
However, conventionally, mitochondrial complex II is not identified as a significant source 
of ROS. But, two potential ROS-producing sites can be identified in mitochondrial complex 
II when its sequence of electron transport is considered together with the spatial arrange-
ment of its redox centers. When one molecule of succinate is oxidized by complex II, FAD is 
reduced with two electrons, but subsequent transfer of electrons through Fe-S clusters occurs 
one at a time. Hence, when one electron is delivered to the proximal Fe-S cluster from FAD, 
a flavin radical is formed until the second electron is delivered. Similarly, after sequential 
transfer of single electrons through Fe-S clusters, quinone is reduced with two electrons. 
Hence, when one electron arrives at the Q site, until another electron arrives from Fe-S clus-
ters, a quinone radical is formed. These two radicals have the potential to generate ROS, if 
there is accessibility to oxygen (Figure 5).
During the past two decades, complex II has emerged as an important source of ROS. On 
the one hand, ROS produced from mutated complex II has been proposed to be the under-
lying cause of complex II–associated human diseases. Thus, numerous studies have been 
conducted to understand ROS production from human complex II. Most of these studies 
have been conducted on model organisms such as Escherichia coli, Saccharomyces cerevisiae, 
and Caenorhabditis elegans [17–20]. A hallmark in these studies is the finding that the mev-1 
mutation in the mitochondrial complex II of C. elegans results in enhanced O
2
− production 
and oxygen hypersensitivity [19, 20]. Later on, this finding was further reinforced by a study 
using a transgenic mouse cell line with the equivalent mutation in the CybL gene as the mev-
1 mutation demonstrating O
2
− overproduction from mitochondria that leads to tumorigen-
esis [21]. More recently, mutations in the Ip subunit in the C. elegans have also been found 
to display enhanced ROS production [22]. Site-directed mutagenesis of CybS subunit in E. 
coli [23] and the Ip and CybS subunits in S. cerevisiae [18, 24] has also shown enhanced ROS 
production providing further support for the hypothesis that ROS underlies the complex II 
mutations-associated carcinogenesis. Indeed, some studies have been conducted on human 
cell lines using pharmacological and genetic interventions to mimic complex II mutations, 
but the results are controversial. For example, ROS production from human mitochondrial 
complex II has been shown by Guzy et al. [25] in intact cells of the hepatoma cell line Hep3B 
by inhibiting the complex II activity by the Q site inhibitor theonyl trifluoroacetone (TTFA) 
and by RNA interference of Ip subunit. In contrast, RNA interference of the same subunit of 
complex II in the same cell line by Cervera et al. have failed to detect ROS production [26].
On the other hand, ROS produced from mitochondrial complex II has received consider-
able attention as a mediator of “mitocans” (a novel class of mitochondrial targeted antican-
cer drugs) induced cancer cell death [5]. Interestingly, complex II Q site inhibiting mitocan, 
ɑ-tocopheryl succinate (ɑ-TOS) has been found to induce ROS only in complex II competent 
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cells but not in complex II mutant cells [27, 28], indicating the importance of a wild-type com-
plex II for its action. More importantly, this complex II inhibitor has caused selective death of 
cancer cells, but the exact reason for this selectivity is not yet understood [29].
Figure 4. Diagrammatic representation of the production of the reactive oxygen species (ROS). When oxygen is reduced 
with a single electron, O
2
− is formed. Superoxide is converted to H
2
O
2
 by the enzyme superoxide dismutase. In the 
presence of transition metals such as Fe2+, H
2
O
2
 is converted into hydroxyl radicals (OH•) by the Fenton reaction.
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In this chapter, we show that the potent and specific complex II Q site inhibitor atpenin A5 
[30] can specifically induce ROS production in two human cancer cell lines HT-29, which pre-
dominantly express Fp I, and DLD-1, which predominantly express Fp II in the mitochondrial 
complex II but not in the noncancerous tissue, human dermal fibroblasts that predominantly 
express Fp I. This difference in ROS production may be attributed to the difference in the post-
translational modifications of the wild-type mitochondrial complex II’s in normal cells and 
cancer cells. This finding highlights new avenues in developing complex II-targeted mitocans 
with considerable promise.
2. Materials and methods
2.1. Culture of cells
Human colon cancer cell lines HT-29, which predominantly express Fp I in its complex II, 
and DLD-1, which predominantly express Fp II in its complex II, were obtained from ETCC 
and grown in glucose-free Roswell Park Memorial Institute (RPMI) medium supplemented 
with 1 g/L of glucose with 10% heated fetal bovine serum, 100 units/mL penicillin, 100 μg/mL 
streptomycin, and 0.25 μg/mL amphotericin B at 37°C and 5% CO
2
 in a humidified incubator. 
The medium was renewed in 48 h intervals, and the cells were harvested at 70% confluence. 
Figure 5. Ribbon model of mitochondrial complex II of Sus scrofa (pdb1ZOY) showing the potential ROS production 
sites. Fp, Ip, CybL, and CybS subunits are shown in green, blue, red, and orange, respectively. The redox centers—FAD, 
iron sulfur clusters, and heme b—are labeled in the figure.
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Human dermal fibroblasts, which predominantly express Fp I in its complex II, were obtained 
from Cell Applications Inc., Japan, and grown in Dulbecco’s Modified Eagle Medium Nutrient 
Mixture F-12 (DMEM-F12).
2.2. Analysis of complex II isoform expression
Analysis of complex II isoform expression was carried out as described previously [8]. Briefly, 
total RNA was isolated from cultured cells using TRIzol LS reagent (Invitrogen) according to the 
manufacturer’s instructions. After removal of residual DNA by treating with DNAse, cDNA was 
synthesized from total RNA using ReverTraAce (Toyobo, Japan) and an oligo (dT) primer. DNA 
sequence of the Fp I subunit of the complex II was amplified using Taq DNA polymerase with 
the sense primer 5′tacggagcaggca 3′ and the antisense primer 5′aatggtggcgggac 3′ and that of the 
Fp II subunit was amplified with the sense primer 5′cggacagaggcg3′ and the antisense primer 
5′aatggctggcgggat3′. The resulting PCR products were subjected to agarose gel electrophoresis, 
and the two isoforms were identified by the size of the PCR products in the ethidium bromide-
stained agarose gels scanned with the electronic transilluminator FAS III (Toyobo, Japan).
2.3. Isolation of mitochondria
Cells cultured in three 225 cm2 flasks were harvested by trypsinization. The cells were sus-
pended in mitochondria preparation buffer (250 mM sucrose, 20 mM HEPES, 3 mM EDTA, and 
1 mM sodium malonate), pH 7.5, and homogenized with a power-driven glass-teflon Potter-
Elvehjem homogenizer (20 passes). The homogenate was centrifuged at 700 × g for 15 min 
to pellet the cell debris and nuclei. The resulting supernatant was centrifuged at 14,000 × g 
for 15 min to sediment the mitochondria. The pellet was washed thrice with the mitochondria 
isolation buffer without sodium malonate, resuspended in the same buffer, and stored on ice 
until analysis. Integrity of the mitochondria was analyzed by citrate synthase activity in the 
presence and absence of 0.05% sucrose monolaurate (SML) in the assay mixture.
2.4. H
2
O
2
 assay in isolated mitochondria
Hydrogen peroxide-mediated oxidation of the fluorescent probe Amplex Red (10-acetyl-
3,7-dihydroxyphenoxazine) to resorufin was used to determine the H
2
O
2
 generation rate 
of the isolated mitochondria as described previously [31, 32]. Since Amplex Red does not 
enter the mitochondria, polyethylene glycol-conjugated SOD (PEG-SOD), a membrane per-
meable form of SOD, was added to the reaction mixture to convert the O
2
− produced in the 
mitochondrial matrix into H
2
O
2
, which is subsequently released to the cytosol. The assay 
was performed in a 96-well plate maintained at 25°C. The resorufin formation rate was 
measured in SpectraMax Plus spectroflourometer (Molecular Devices, Sunnyvale, CA) at an 
excitation wavelength of 540 nm and emission wavelength of 590 nm. The H
2
O
2
 generation 
rate was calculated using a standard curve (0–1000 nmol/ml). To eliminate the fluorescence 
increment due to nonspecific oxidation of Amplex Red, a parallel assay was performed 
in the presence of catalase, an enzyme that scavenges H
2
O
2
, and the result was obtained 
by subtracting the amount of H
2
O
2
 produced in the presence of catalase from that in the 
absence of catalase.
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H
2
O
2
 generation assays were also performed in the presence of respiratory chain inhibitors-10 mM 
nitropropionic acid (NPA), which blocks the dicarboxylate-binding site of complex II; 10 μM 
atpenin A5, which blocks the Q site of complex II; and 10 μM antimycin A, which blocks the Qi 
site of complex III in order to dissect the specific ROS-producing site of the respiratory chain.
2.5. Superoxide assay in intact cells
MitoSOX Red is a fluorescent probe that is targeted to the mitochondria of intact cells and 
oxidized by O
2
− produced within mitochondria. This probe was used to detect O
2
− production 
in the intact cells as previously described with slight modifications [33, 34]. Briefly, DLD-1 and 
HT-29 colon epithelial cells and the human dermal fibroblasts were cultured on cover slips and 
loaded with 5 μM MitoSOX Red and 50 nM MitoTracker Green (Molecular Probes, Eugene, 
OR) in the dark at 37°C in the CO
2
 incubator for 15 min. After washing the cells for three times 
with prewarmed phosphate-buffered saline (PBS), three cover slip cultures each from DLD-1 
and HT-29 cells were treated with the vehicle (0.2% DMSO), PEG-SOD or 10 mM NPA and 
incubated for 30 min. Thereafter, 10 μM atpenin A5 was added to all the cover slip cultures 
and imaged at 488 nm/455 nm excitation and emission wavelengths for MitoTracker Green and 
633/650 nm for MitoSOX Red immediately (0 min images) and after 30 min (30 min images), 
using a confocal laser scanning microscope (LSM 510, Carl Zeiss, Germany). The two cover 
slip cultures of dermal fibroblasts were treated with 0.2% DMSO for 30 min, and subsequently 
one was treated with 10 μM atpenin A5 and the other one was treated with 1 μM antimycin 
A. Image acquisition of dermal fibroblasts was done similar to those of DLD-1 and HT-29 cells.
2.6. Statistical analysis
Results of the H
2
O
2
 assay are expressed as means ± SEM of three independent experiments. 
The data were analyzed using Shapiro-Wilks test followed by one way ANOVA. Subsequently, 
Levene’s test and Tuckey’s post hoc tests were performed. The level of significance was 
P < 0.05. Graph Pad Prism software (version 7, USA) was used for the analysis.
3. Results
3.1. Complex II isoforms in cell lines
cDNA from the two cancer cell lines (HT-29 and DLD-1) and the normal cell line (dermal fibro-
blasts) were amplified using Fp I- and Fp II-specific primers to analyze the degree of expres-
sion of the two Fp types in complex II isoforms. As shown in Figure 6, the results revealed that 
HT-29 and DLD-1 cells predominantly express Fp I and Fp II, respectively, in their complex II, 
whereas dermal fibroblasts predominantly express Fp I.
3.2. H
2
O
2
 production from the complex II in isolated mitochondria
As shown by the first bar of Figure 7a–c, mitochondria isolated from all three cell lines generated 
H
2
O
2
 when incubated with succinate in the absence of any respiratory chain inhibitors. This result 
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shows that mitochondrial complex II in all three cell lines under investigation can rapidly oxidize 
succinate and feed electrons to their respiratory chains and a portion of those electrons are leaked 
to O
2
 to generate ROS.
The second bar in Figure 7a–c shows that addition of atpenin A5, an inhibitor of the Q-binding 
site of complex II, increases the H
2
O
2
 production in mitochondria isolated from HT-29 and 
DLD-1 cells but not in the mitochondria isolated from dermal fibroblasts. It shows that when 
electron flow through the Q-binding site is blocked, increase in the proton motive force in 
the respiratory chain proximal to the complex II Q site leads to leakage of electrons from the 
respiratory chain to oxygen in mitochondria isolated from cancer cells but not in mitochondria 
isolated from normal cells. This observation implies that a site proximal to the Q-binding site 
of complex II is responsible for leakage of electrons in cancer cell respiratory chains, which 
is different from that in normal cells. As shown by the third bar of the Figure 7a–c, addition 
of NPA, an inhibitor of the dicarboxylate-binding site of the mitochondrial complex II, along 
with atpenin A5 almost completely abolished the succinate-dependent H
2
O
2
 production in 
all three cell types. According to this observation, the increment in H
2
O
2
 production from the 
mitochondria isolated from cancer cells in the presence of atpenin A5 is attributed to a leakage 
of electrons from a site upstream of the Q site and downstream of the dicarboxylate-binding 
site. However, one can argue that the difference observed in H
2
O
2
 production between mito-
chondria of cancer cells and normal cells in the presence of atpenin A5 is due to the difference 
in the antioxidant defense systems between the two cell types. Therefore, we observed the 
H
2
O
2
 production in isolated mitochondria in the presence of antimycin A, an inhibitor of the 
Qi site of complex III that is reported to induce ROS generation from the respiratory chain 
complex III [32]. As shown by the fourth bar of Figure 7a–c, addition of antimycin A to the 
reaction mixture could increase the H
2
O
2
 production from mitochondria isolated from cancer 
cells as well as from the normal cells, indicating that the difference in the antioxidant levels 
is not the case.
3.3. Superoxide production from the complex II in live cells
When HT-29 and DLD-1 cells grown in RPMI medium containing glucose were treated with 
atpenin A5, their confocal images showed a clear red fluorescence in the cytoplasm while the 
untreated cells were devoid of such red fluorescence. To verify the localization of this fluo-
rescence to mitochondria, the cells were simultaneously loaded with MitoTracker Green, a 
Figure 6. Mitochondrial complex II isoforms expression pattern in HT-29, DLD-1, and dermal fibroblasts. Ethidium 
bromide-stained agarose gels show the RT-PCR products obtained with Fp-specific primers using the RNA isolated 
from HT-29, DLD-1, and dermal fibroblasts. Isoform I is comprised of Fp I and isoform II is comprised of Fp II.
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Figure 7. H
2
O
2
 production from the mitochondria isolated from HT-29 cells (a), DLD-1 cells (b), and dermal fibroblasts 
(c) oxidizing 0.75 mM succinate. Results are expressed as mean ± SEM of three independent experiments. *Significantly 
different from control cells (P < 0.05).
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Figure 8. Confocal laser scanning microscopic images showing the O
2
− production from the mitochondrial complex II in 
live cells. Panels A, D, and G show the time lapse images of the cells preincubated with DMSO and treated with atpenin 
A5. Panels B and E show the cells preincubated with SOD-PEG and treated with atpenin A5. Panels C and F show the 
cells preincubated with NPA and treated with atpenin A5. Cells treated with antimycin A are shown in panel H. The 
cells in the first column have a green florescence. The cells in the second column have a red florescence. Out of the cells 
in the third column, A2, D2 and H2 panels have a dark orange florescence and  B2, C2 and E2 panels have a light orange 
florescence and other panels have a green florescence.
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fluorescent probe that is specifically targeted to mitochondria. The resulting confocal images 
revealed that the green fluorescence of MitoTracker Green colocalize with the red fluorescence 
of MitoSOX Red indicating that MitoSOX Red is oxidized within mitochondria (Figure 8). To 
determine whether MitoSOX oxidation is a superoxide-dependent process, the cells were pre-
incubated with PEG-SOD, which can scavenge O
2
− generated within cells. In the presence of 
PEG-SOD, MitoSOX Red fluorescence was negligible (Figure 8, panels B and E). This result 
indicates that the majority of the atpenin A5-induced MitoSOX fluorescence is superoxide 
dependent. Next, we attempted to determine whether the atpenin A5-induced O
2
− production 
is a succinate-dependent process by preincubating the cells with NPA before adding atpenin 
A5. As shown in Figure 8 panels C and F, the MitoSOX Red fluorescence intensity in the NPA-
treated cells was markedly reduced indicating that the atpenin A5-induced MitoSOX Red oxi-
dation is a succinate-dependent event. Collectively, these data indicate that atpenin A5 induces 
succinate-dependent O
2
− production from the mitochondrial complex II within intact DLD-1 
and HT-29 cells. In agreement with the results from the isolated mitochondria, addition of 
atpenin A5 to the MitoSOX Red-loaded dermal fibroblasts did not display any red fluorescence 
(Figure 8 panel G) indicating that atpenin A5 does not induce O
2
− production in mitochondria 
of dermal fibroblasts. But dermal fibroblasts showed an increment in red fluorescence with 
antimycin A (Figure 8 panel H). This observation shows that the mitochondria of the dermal 
fibroblasts can produce O
2
− when the Q site of complex III is inhibited by antimycin A.
4. Discussion
ROS are produced from the mitochondrial complex II of the cancer cells (DLD-1 and HT-29) 
but not from the normal cells (dermal fibroblasts) when the entry of electrons to its quinone-
binding site is blocked with 10 μM atpenin A5. However, previous studies in our labora-
tory have revealed that quinone reduction in the mitochondrial complex II can be completely 
inhibited at the tested concentration of atpenin A5 [8, 10]. Therefore, the difference in ROS 
production between cancer cells and normal cells may be attributed to a difference in the com-
plex IIs that is upstream of the atpenin A5-binding site. Since the dicarboxylate-binding site 
inhibitor, NPA, could inhibit the ROS production induced by atpenin A5 in cancer cells, it is 
concluded that the ROS-producing site must be within the complex II, upstream of the atpenin 
A5 inhibition site(Q site) and downstream of NPA-binding site (dicarboxylate-binding site). 
According to previous evidence, the most likely ROS-producing sites of mitochondrial com-
plex II are FAD [35–37] site and the Q site [37–39]. Observations of this study show that the 
ROS-generating site of complex II in atpenin A5-treated cancer cells is FAD but not Q site.
In order to explain this observation, we analyzed the published data on the crystal struc-
tures of flavoproteins, which are available in both the substrate bound and unbound forms 
[40–42]. They have shown that the capping domain in Fp subunit rotates during the enzyme 
catalysis. When the active site is not occupied by the substrate, the capping domain is 
rotated away from the active site creating a solvent channel linking the active site and the 
surrounding aqueous environment. In the substrate bound state, the capping domain is 
rotated inward concealing the active site, preventing the access of solvent to the active site 
[37]. Thus, closed conformation acquired during enzyme catalysis appears to be vital for 
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preventing the electron leak into oxygen. It appears that differences in the three-dimensional 
structure of the capping domain of the enzyme contribute to the difference in ROS produc-
tion in cancer cells and normal cells. In fact, previous studies in our laboratory have shown 
that DLD-1 and HT-29 cells display FRD activity associated with the phosphorylation status 
of the Fp subunit of complex II and the degree of phosphorylation has been increased under 
hypoxic and hypoglycemic conditions [11]. If phosphorylation of amino acid residues in the 
Fp subunit can affect the correct movement of the capping domain during succinate oxida-
tion, it will be possible for the electrons to leak to oxygen from the FAD site.
Our observation of a 1.5-fold higher ROS production from isolated mitochondria of DLD-1 
cells than that of HT-29 cells may also have resulted due to the difference in the phosphoryla-
tion status of the two isoforms because the amino acids, which differ in the two isoforms, are 
found in the C-terminal domain of the Fp subunit, which plays an important role in opening 
and closing of the active site of the complex II enzymes [9] Substitution of tyrosine 629 in Fp 
I with phenylalanine in Fp II may affect the phosphorylation state of the C-terminal domain 
since tyrosine is a possible phosphorylation site while phenylalanine is not. This difference 
may affect the closing of the active site in Fp II during enzyme catalysis and allow more elec-
trons to leak to oxygen from FAD. However, it is essential to resolve the crystal structure of 
the two isoforms of the human mitochondrial complex II with both the open and closed states 
of the capping domain and to establish the relationship between the phosphorylation status 
of the Fp subunit and the ROS production.
In summary, complex II Q site inhibitor atpenin A5 differentially affects the ROS produc-
tion in normal cells and cancer cells. This difference may be utilized for selective destruc-
tion of cancer cells using complex II-inhibiting mitocans. We hypothesize that the difference 
in ROS production observed in this study is attributed to the difference in posttranslational 
modifications of mitochondrial complex II between normal cells and cancer cells, which 
may be more pronounced under hypoxic and hypoglycemic tumor microenvironments.
Acknowledgements
Ministry of Education, Culture and Sports in Japan is gratefully acknowledged for their financial 
support.
Author details
Madhavi P. Paranagama1* and Kiyoshi Kita2
*Address all correspondence to: madhaviparanagama@gmail.com
1 Department of Basic Sciences, Faculty of Dental Sciences, University of Peradeniya, 
Peradeniya, Sri Lanka
2 School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
Differential Effect of Atpenin A5 on ROS Production from Wild-Type Mitochondrial Complex II…
http://dx.doi.org/10.5772/intechopen.71638
103
References
[1] Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW. The genetics and pathology of 
mitochondrial disease. The Journal of Pathology. 2017;241(2):236-250
[2] Hoekstra AS, Bayley JP. The role of complex II in disease. Biochimica et Biophysica Acta. 
2013;1827(5):543-551
[3] Kita K, Shiomi K, Omura S. Advances in drug discovery and biochemical studies. Trends 
in Parasitology. 2007;23(5):223-229
[4] Sakai C, Tomitsuka E, Esumi H, Harada S, Kita K. Mitochondrial fumarate reductase as 
a target of chemotherapy: From parasites to cancer cells. Biochimica et Biophysica Acta. 
2012;1820(5):643-651
[5] Kluckova K, Bezawork-Geleta A, Rohlena J, Dong L, Neuzil J. Mitochondrial complex II, 
a novel target for anti-cancer agents. Biochimica et Biophysica Acta. 2013;1827(5):552-564
[6] Ackrell BA. Progress in understanding structure-function relationships in respiratory 
chain complex II. FEBS Letters. 2000;466(1):1-5
[7] Iverson TM. Catalytic mechanisms of complex II enzymes: A structural perspective. 
Biochimica et Biophysica Acta. 2013;1827(5):648-657
[8] Tomitsuka E, Goto Y, Taniwaki M, Kita K. Direct evidence for expression of type II flavo-
protein subunit in human complex II (succinate-ubiquinone reductase). Biochemical and 
Biophysical Research Communications. 2003;311(3):774-779
[9] Tomitsuka E, Hirawake H, Goto Y, Taniwaki M, Harada S, Kita K. Direct evidence for 
two distinct forms of the flavoprotein subunit of human mitochondrial complex II (suc-
cinate-ubiquinone reductase). Journal of Biochemistry. 2003;134(2):191-195
[10] Sakai C, Tomitsuka E, Miyagishi M, Harada S, Kita K. Type II Fp of human mitochon-
drial respiratory complex II and its role in adaptation to hypoxia and nutrition-deprived 
conditions. Mitochondrion. 2013;13(6):602-609
[11] Tomitsuka E, Kita K, Esumi H. Regulation of succinate-ubiquinone reductase and fuma-
rate reductase activities in human complex II by phosphorylation of its flavoprotein 
subunit. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences. 
2009;85(7):258-265
[12] Cecchini G. Function and structure of complex II of the respiratory chain. Annual Review 
of Biochemistry. 2003;72:77-109
[13] Kita K, Takamiya S. Electron-transfer complexes in Ascaris mitochondria. Advances in 
Parasitology. 2002;51:95-131
[14] Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative 
metabolome profiling of colon and stomach cancer microenvironment by capillary elec-
trophoresis time-of-flight mass spectrometry. Cancer Research. 2009;69(11):4918-4925
[15] Murphy MP. How mitochondria produce reactive oxygen species. The Biochemical 
Journal. 2009;417(1):1-13
Mitochondrial Diseases104
[16] Jezek P, Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and 
 organism. The International Journal of Biochemistry & Cell Biology. 2005;37(12):2478-2503
[17] Messner KR, Imlay JA. Mechanism of superoxide and hydrogen peroxide formation by 
fumarate reductase, succinate dehydrogenase, and aspartate oxidase. The Journal of 
Biological Chemistry. 2002;277(45):42563-42571
[18] Guo J, Lemire BD. The ubiquinone-binding site of the Saccharomyces cerevisiae succi-
nate-ubiquinone oxidoreductase is a source of superoxide. The Journal of Biological 
Chemistry. 2003;278(48):47629-47635
[19] Ishii N, Fujii M, Hartman PS, Tsuda M, Yasuda K, Senoo-Matsuda N, et al. A mutation 
in succinate dehydrogenase cytochrome b causes oxidative stress and ageing in nema-
todes. Nature. 1998;394(6694):694-697
[20] Senoo-Matsuda N, Yasuda K, Tsuda M, Ohkubo T, Yoshimura S, Nakazawa H, et al. A 
defect in the cytochrome b large subunit in complex II causes both superoxide anion 
overproduction and abnormal energy metabolism in Caenorhabditis elegans. The Journal 
of Biological Chemistry. 2001;276(45):41553-41558
[21] Ishii T, Yasuda K, Akatsuka A, Hino O, Hartman PS, Ishii NA. Mutation in the SDHC 
gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. 
Cancer Research. 2005;65(1):203-209
[22] Huang J, Lemire BD. Mutations in the C. elegans succinate dehydrogenase iron-sulfur 
subunit promote superoxide generation and premature aging. Journal of Molecular 
Biology. 2009;387(3):559-569
[23] Zhao Z, Rothery RA, Weiner JH. Effects of site-directed mutations in Escherichia coli suc-
cinate dehydrogenase on the enzyme activity and production of superoxide radicals. 
Biochemistry and Cell Biology. 2006;84(6):1013-1021
[24] Szeto SS, Reinke SN, Sykes BD, Lemire BD. Ubiquinone-binding site mutations in the 
Saccharomyces cerevisiae succinate dehydrogenase generate superoxide and lead to the 
accumulation of succinate. The Journal of Biological Chemistry. 2007;282(37):27518-27526
[25] Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SdhB, but not the 
SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible 
factor activation and tumorigenesis. Molecular and Cellular Biology. 2008;28(2):718-731
[26] Cervera AM, Apostolova N, Crespo FL, Mata M, McCreath KJ. Cells silenced for SDHB 
expression display characteristic features of the tumor phenotype. Cancer Research. 
2008;68(11):4058-4067
[27] Dong LF, Low P, Dyason JC, Wang XF, Prochazka L, Witting PK, et al. Alpha-tocopheryl 
succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial 
respiratory complex II. Oncogene. 2008;27(31):4324-4335
[28] Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M, et al. Suppression 
of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory 
complex II. Clinical Cancer Research. 2009;15(5):1593-1600
[29] Angulo-Molina A, Reyes-Leyva J, Lopez-Malo A, Hernandez J. The role of alpha tocopheryl 
succinate (alpha-TOS) as a potential anticancer agent. Nutrition and Cancer. 2014;66(2):167-176
Differential Effect of Atpenin A5 on ROS Production from Wild-Type Mitochondrial Complex II…
http://dx.doi.org/10.5772/intechopen.71638
105
[30] Miyadera H, Shiomi K, Ui H, Yamaguchi Y, Masuma R, Tomoda H, et al. Atpenins, 
potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxi-
doreductase). Proceedings of the National Academy of Sciences of the United States of 
America. 2003;100(2):473-477
[31] Mohanty JG, Jaffe JS, Schulman ES, Raible DG. A highly sensitive fluorescent micro-
assay of H
2
O
2
 release from activated human leukocytes using a dihydroxyphenoxazine 
derivative. Journal of Immunological Methods. 1997;202(2):133-141
[32] Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive 
oxygen species by mitochondria: Central role of complex III. The Journal of Biological 
Chemistry. 2003;278(38):36027-36031
[33] Mukhopadhyay P, Rajesh M, Hasko G, Hawkins BJ, Madesh M, Pacher P. Simultaneous 
detection of apoptosis and mitochondrial superoxide production in live cells by flow 
cytometry and confocal microscopy. Nature Protocols. 2007;2(9):2295-2301
[34] Robinson KM, Janes MS, Beckman JS. The selective detection of mitochondrial superox-
ide by live cell imaging. Nature Protocols. 2008;3(6):941-947
[35] Ohnishi T, King TE, Salerno JC, Blum H, Bowyer JR, Maida T. Thermodynamic and elec-
tron paramagnetic resonance characterization of flavin in succinate dehydrogenase. The 
Journal of Biological Chemistry. 1981;256(11):5577-5582
[36] Maklashina E, Iverson TM, Sher Y, Kotlyar V, Andrell J, Mirza O, et al. Fumarate reduc-
tase and succinate oxidase activity of Escherichia coli complex II homologs are per-
turbed differently by mutation of the flavin binding domain. The Journal of Biological 
Chemistry. 2006;281(16):11357-11365
[37] Paranagama MP, Sakamoto K, Amino H, Awano M, Miyoshi H, Kita K. Contribution of 
the FAD and quinone binding sites to the production of reactive oxygen species from 
Ascaris suum mitochondrial complex II. Mitochondrion. 2010;10(2):158-165
[38] Salerno JC, Ohnishi T. Studies on the stabilized ubisemiquinone species in the succinate-
cytochrome c reductase segment of the intact mitochondrial membrane system. The 
Biochemical Journal. 1980;192(3):769-781
[39] Tran QM, Rothery RA, Maklashina E, Cecchini G, Weiner JH. The quinone binding site 
in Escherichia coli succinate dehydrogenase is required for electron transfer to the heme 
b. The Journal of Biological Chemistry. 2006;281(43):32310-32317
[40] Yamashita T, Ino T, Miyoshi H, Sakamoto K, Osanai A, Nakamaru-Ogiso E, et al. Rhodo- 
quinone reaction site of mitochondrial complex I, in parasitic helminth, Ascaris suum. 
Biochimica et Biophysica Acta. 2004;1608(2-3):97-103
[41] Yankovskaya V, Horsefield R, Tornroth S, Luna-Chavez C, Miyoshi H, Leger C, et al. 
Architecture of succinate dehydrogenase and reactive oxygen species generation. Science. 
 2003;299(5607):700-704
[42] Yu L, Xu JX, Haley PE, Yu CA. Properties of bovine heart mitochondrial cytochrome b560. 
The Journal of Biological Chemistry. 1987;262(3):1137-1143
Mitochondrial Diseases106
